Analyst Price Targets — BLTE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2026 11:41 am | Yi Chen | H.C. Wainwright | $200.00 | $171.51 | StreetInsider | Belite Bio, Inc, ADR (BLTE) PT Raised to $200 at H.C. Wainwright |
| March 3, 2026 1:18 pm | — | Needham | $217.00 | $177.50 | StreetInsider | Belite Bio, Inc, ADR (BLTE) PT Raised to $217 at Benchmark Following Business Update |
| February 19, 2026 12:17 pm | Graig Suvannavejh | Mizuho Securities | $223.00 | $173.91 | TheFly | Belite Bio price target raised to $223 from $194 at Mizuho |
| January 6, 2026 10:00 am | — | Morgan Stanley | $191.00 | $159.42 | TheFly | Belite Bio initiated with an Overweight at Morgan Stanley |
| December 3, 2025 1:44 pm | — | BTIG | $187.00 | $153.70 | StreetInsider | Belite Bio, Inc, ADR (BLTE) PT Raised to $187 at Benchmark on Positive Phase 3 Dragon Trial Results |
| December 2, 2025 8:05 pm | — | Maxim Group | $200.00 | $150.84 | TheFly | Belite Bio price target raised to $200 from $140 at Maxim |
| December 2, 2025 10:11 am | Graig Suvannavejh | Mizuho Securities | $194.00 | $154.02 | TheFly | Belite Bio upgraded to Outperform from Neutral at Mizuho |
| December 1, 2025 4:32 pm | — | H.C. Wainwright | $185.00 | $153.65 | TheFly | Belite Bio price target raised to $185 from $98 at H.C. Wainwright |
| November 20, 2025 10:44 am | — | Mizuho Securities | $105.00 | $120.37 | TheFly | Belite Bio initiated with a Neutral at Mizuho |
| August 13, 2024 6:21 am | Yi Chen | H.C. Wainwright | $60.00 | $48.55 | TheFly | Belite Bio price target raised to $60 from $59 at H.C. Wainwright |
Latest News for BLTE
Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE - Get Free Report) Director Wan-Shan Chen sold 1,100 shares of the company's stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $180.43, for a total value of $198,473.00. Following the transaction, the director directly owned 9,096 shares in the company,
Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE - Get Free Report) CFO Hao-Yuan Chuang sold 6,200 shares of the business's stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $181.50, for a total transaction of $1,125,300.00. Following the transaction, the chief financial officer owned 93,800 shares
Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE - Get Free Report) CEO Yu-Hsin Lin sold 9,200 shares of the stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $181.45, for a total value of $1,669,340.00. Following the completion of the sale, the chief executive officer directly
Shares of Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE - Get Free Report) have earned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, as filed with the Securities and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BLTE.
U.S. House Trading
No House trades found for BLTE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.